This Is MS Multiple Sclerosis Knowledge & Support Community

Diabetes Incidence According to Statin Intensity Regimen, Body Mass Index, and Cardiorespiratory Fitness Mayo Clin Proc. 2025 Oct 1:S0025-6196(25)00336-2. Objective : To evaluate the association between statin therapy, cardiorespiratory fitness (CRF), body mass index (BMI), and type 2 diabetes mell...

Can supplementation with antioxidants improve cognitive functions in patients with multiple sclerosis? A literature review Ann Med Surg (Lond). 2025 Apr 16;87(5):2736-2748. Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease of the central nervous system (CNS) with ...

Helius changes its name to reflect its new business focus in cryptocurrency. Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation September 29, 2025 https://www.globenewswire.com/news-release/2025/09/29/315...

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis September 25, 2025 https://imux.com/immunic-presented-key-vidofludimus-calcium-data-at-the-41st-congress-of-ectrims-highlighting-its-potential-in-multiple-sclerosis/ • V...

Gabapentinoids and Risk for Exacerbation of Chronic Obstructive Pulmonary Disease Ann Am Thorac Soc. 2025 Jul 16. Rationale : Data on the effect of gabapentinoids on patients with chronic obstructive pulmonary disease (COPD) are sparse, although the U.S. Food and Drug Administration has issued a sa...

There's been a shakeup at Helius. They have a new director and they're also entering the crypto business. What this means for the PoNS remains to be seen though. Pantera-Backed Solana Treasury Firm Helius Raises $500M, Stock Soars Over 200% The firm aims to accumulate Solana's SOL, competing with re...

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial September 9, 2025 https://www.globenewswire.com/news-release/2025/09/09/3146779/29248/en/Anavex-Life-Sciences...

DMDs reduce lesions in late-onset MS, but don't reduce disability progression. Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis Neurology. 2025 Aug 12;105(3):e213744. Background and objectives : The therapeutic strategy in patients with late-onset MS (LOMS) remains p...

Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference Neurology. 2023 Mar 21;100(12):e1296-e1308. Background and objectives : The question of the long-term safety of pregnancy is a major concern in patients with multiple sclerosis (MS), but its s...

Will Olive Oil Protect Your Brain ? Both people and mice getting extra-virgin olive oil in their diets had better cognitive function. It could protect your brain as well. Terry Graedon - August 11, 2025 https://www.peoplespharmacy.com/articles/will-olive-oil-protect-your-brain Scientists have found...

New Concerns About Gabapentin and Pregabalin (Lyrica) for Nerve Pain Concerns about gabapentin and pregabalin prescriptions now include heart failure as well as dementia. What's going on? Joe Graedon - August 07, 2025 https://www.peoplespharmacy.com/articles/new-concerns-about-gabapentin-and-pregab...

Could A PERSONALIZED Exercise Program Save Your Brain? Randomized controlled trials answer the question: Could exercise save your brain? with yes. Following a DASH diet as well may help even more. Joe Graedon - July 31, 2025 https://www.peoplespharmacy.com/articles/could-exercise-save-your-brain Th...

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease July 31, 2025 07:30 ET https://www.globenewswire.com/news-release/2025/07/31/3124886/29248/en/Anavex-Life-Sci...

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study Ann Neurol. 2025 Aug;98(2):294-307. Objective : To compare clinical and radiological outcomes among relapsing multiple sclerosis patie...

This trial was terminated early due to excessive inflammatory disease activity in the discontinuation treatment arm. Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial JAMA Neurol. 2025 Feb 1;82(2):123-131. Importa...